Skip to main content
. 2005 Aug;3(3):157–165. doi: 10.3121/cmr.3.3.157

Table 2.

Response to 90Y-ibritumomab tiuxetan and 131I-tositumomab in relapsed/refractory low- to intermediate-grade NHL

Investigator Patients/Prior Therapy Percent CR Percent PR
90Y-ibritumomab tiuxetan
Knox 199622 18/+ 34 38
Witzig 199923 51/+ 26 41
Witzig 200224 57/+ 15 59
Witzig 200225 143/+ 30 50
131I-tositumomab
Kaminski 200019 59/+ 34 36
Vose 200020 47/+ 32 25
Kaminski 200121 60/+ 20 45

CR, complete response; PR, partial response; +, received prior therapy